Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's New Drug Application for Anaphylm [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Aquestive between June 16, 2025, and January 8, 2026, to discuss their legal options [1]. - A federal securities class action has been filed against Aquestive, with a deadline of May 4, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that the company and its executives made false and misleading statements regarding the approval timeline for Anaphylm, leading to artificially inflated stock prices [4]. Group 2: Stock Price Impact - Following the announcement on January 9, 2026, regarding deficiencies identified by the FDA in the NDA for Anaphylm, Aquestive's stock price dropped by more than 37% on the same day [5]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to allegations of misleading statements regarding the efficacy of its drug setrusumab in treating Osteogenesis Imperfecta, which led to significant stock price declines following the announcement of study failures [2][4][5][6]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Ultragenyx to contact them to discuss legal options [1]. - The firm is reminding investors of the April 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Ultragenyx [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Ultragenyx - The complaint alleges that Ultragenyx and its executives violated federal securities laws by making false or misleading statements about the effects of setrusumab and downplaying the risks associated with the Phase III Orbit study [4]. - Ultragenyx's Phase III Orbit study failed to achieve statistical significance for the second interim analysis, leading to a stock price drop of over 25% on July 9, 2025 [5]. - On December 29, 2025, Ultragenyx announced that both its Phase III Orbit and Cosmic Studies did not achieve statistical significance against primary endpoints, resulting in a further stock price decline of over 42% [6][7]. Group 3: Class Action Details - The lead plaintiff in a class action is defined as the investor with the largest financial interest who directs and oversees the litigation on behalf of the class [8]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [8]. Group 4: Call for Information - Faruqi & Faruqi, LLP is also seeking information regarding Ultragenyx's conduct from whistleblowers, former employees, shareholders, and others [9].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, Inc. due to allegations of violations of federal securities laws related to misleading statements and inadequate disclosures regarding the company's product development and regulatory prospects [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in Inovio to contact them directly to discuss their legal options [1]. - There is a deadline of April 7, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Inovio [2]. - The complaint alleges that Inovio and its executives made false statements regarding the manufacturing of the CELLECTRA device and the prospects of the INO-3107 Biologics License Application (BLA) [4]. Group 2: Regulatory Developments - On December 29, 2025, the FDA accepted Inovio's BLA for INO-3107 but indicated that the company did not provide sufficient information for accelerated approval [5]. - Inovio's stock price fell by $0.56 per share, or 24.45%, closing at $1.73 per share following the FDA's announcement [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3].

Core Insights - The weight loss market is expanding, and while Eli Lilly and Novo Nordisk are current leaders, other companies like Regeneron and Roche are emerging as potential investment opportunities due to their diversified portfolios and innovative products. Group 1: Regeneron - Regeneron reported strong phase 2 results for its weight-loss candidate, trevogrumab, which minimizes muscle loss in patients taking GLP-1 medicines, averting about half of the lean mass loss associated with semaglutide [3][4] - Regeneron's approach allows trevogrumab to be prescribed alongside existing treatments like Wegovy, avoiding direct competition with market leaders [4] - The company is also developing a GLP-1 medicine, olatorepatide, with phase 3 studies expected to start this year, indicating potential for significant clinical progress [6] - Regeneron's primary growth driver is Dupixent, an eczema treatment, and it has a vast pipeline that could lead to additional product launches in the coming years [7] Group 2: Roche - Roche reported strong phase 2 results for its anti-obesity candidate, CT-388, showing a placebo-adjusted weight loss of 22.5% over 48 weeks at the highest dose, positioning it competitively against leading weight-loss drugs [8] - The company is preparing for phase 3 studies to confirm these results, establishing itself as a notable player in the next-generation obesity medicine race [8] - Roche has a diversified healthcare business with several growth drivers in pharmaceuticals, including Ocrevus for multiple sclerosis and Vabysmo, alongside a deep pipeline of 66 new molecular entities [10]

Core Viewpoint - The expiration of the core compound patent for semaglutide in March 2026 will lead to significant changes in the global pharmaceutical market, particularly in the weight loss drug sector, as generic manufacturers prepare to enter the market [4][5]. Patent Expiration and Legal Battles - The core compound patent for semaglutide, originally set to expire in March 2026, faced challenges from East China Pharmaceutical, which initiated a patent invalidation in 2021. Despite a series of legal battles, the patent was upheld until the end of 2025, but its expiration will allow generic drug companies to enter the market [5]. - Although the compound patent will expire, Novo Nordisk's indication patent remains valid until 2037, which may lead to further patent disputes if generic companies seek to market weight loss indications [7]. Domestic Competition - At least 10 domestic companies, including Jiuzhou Gene, Lijun Group, East China Pharmaceutical, and Qilu Pharmaceutical, have submitted applications for semaglutide, with over 10 additional products in clinical phase III trials. The primary focus remains on type 2 diabetes, but weight loss indications are also being pursued rapidly [8]. Price Competition - The entry of multiple domestic semaglutide products is expected to lead to a significant drop in market prices, potentially entering a "bargain" era for weight loss drugs. Novo Nordisk has already reduced the price of its semaglutide injection by nearly 50% in anticipation of this competition [9]. Strategic Shifts - Novo Nordisk is shifting its strategic focus from patent battles to innovation, having received FDA approval for an oral version of semaglutide, Wegovy, which is expected to enhance patient compliance. The product is set to launch in the U.S. in January 2026 [10]. Market Impact - The expiration of the semaglutide patent is expected to benefit patients significantly, as the availability of generic options will lower treatment costs, making it more accessible to a broader patient population. The competition in the GLP-1 market will transition from patent disputes to factors like production capacity, cost control, distribution channels, and brand marketing [11].

Core Viewpoint - Eli Lilly's new long-acting insulin receptor agonist, Eloralintide, has received approval from China's CDE and will initiate three global pivotal Phase III clinical studies, marking a significant advancement in metabolic health [4]. Clinical Research Results and Advantages - Eloralintide has a plasma half-life of approximately 14 days, allowing for weekly subcutaneous injections, enhancing patient convenience [6]. - In Phase II clinical trials, Eloralintide demonstrated a significant dose-dependent weight loss effect, with the highest dose group achieving a weight reduction of 20.1% and an average waist circumference reduction of 17.1 cm, far exceeding the placebo group [6]. - The drug not only aids in weight loss but also improves multiple cardiovascular risk indicators, including blood pressure, blood lipids, and blood glucose, while showing good safety across all dosage groups [6]. - A dose escalation scheme further reduces gastrointestinal discomfort, ensuring patients can continue treatment [6]. Global Phase III Clinical Studies - The three Phase III clinical studies launched in China address the treatment needs of different obesity populations, including studies on obese/overweight patients without type 2 diabetes, obese patients with diabetes, and combination therapy for patients with poor response to incretin drugs [7]. - Eli Lilly's Vice President and General Manager for China stated that the launch of Eloralintide in China is a significant expansion of the company's research footprint in metabolic diseases, aiming for global simultaneous market entry [7]. - The company is building a multi-dimensional obesity treatment solution, incorporating various drug types to meet individual patient needs and drive innovation in obesity treatment [7].

Economic Overview - The US economy shed 92,000 jobs in February, with the unemployment rate rising slightly to 4.4% [1] - Despite the weak jobs report, the market did not interpret it as bad news, indicating underlying resilience in the economy [2][3] Labor Market Insights - Factors contributing to the negative job numbers include weather issues, strikes, and complications in the net birth-death model for new businesses [3] - Leading economic indicators suggest potential signs of improvement in the labor market, with immigration levels significantly reduced from approximately 3 million per year (2014-2022) to around 500,000 per year currently [4][5] Economic Growth Drivers - The economy is expected to benefit from several tailwinds, including a significant bill projected to add 0.9% to GDP growth this year, advancements in AI and data center spending, and a resurgence in domestic production across various sectors [5][6] - Current economic indicators, such as ISM for services and manufacturing, suggest continued growth in the economy over the coming months [7] Inflation and Interest Rates - Current inflation stands at 3.0%, above the Federal Reserve's target of 2%, complicating the possibility of interest rate cuts [8][9] - The expectation is that if the recent job data is an anomaly, growth will persist, making it challenging for the Federal Reserve to lower interest rates [9][10] Market Dynamics - The "Magnificent 7" stocks have begun to underperform, while margin debt remains high, creating a unique market situation where overall index volatility is low, but individual stock volatility is high [11][12] - The market is experiencing significant fluctuations as it assesses which sectors will benefit from AI advancements, leading to increased volatility among individual components of the S&P 500 [12][13] Credit Market Analysis - Default rates for high-yield loans and other lower-rated assets have been declining over the past nine months, indicating a strengthening economy rather than a credit cycle downturn [17][18] - Current issues in the private credit market are viewed as idiosyncratic rather than systemic, aligning with the overall positive economic outlook [18][19]

New York, New York--(Newsfile Corp. - March 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: If you purchased Corcept common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen ...

Core Viewpoint - The long-standing dispute between Novo Nordisk and Hims & Hers Health is reportedly coming to an end, with both companies set to announce a new partnership allowing Novo to sell its weight-loss drug Wegovy through Hims' platform [1][2]. Group 1: Partnership Details - Novo Nordisk plans to sell its weight-loss drugs on Hims & Hers Health's platform, marking a significant shift in their relationship [2]. - The two companies had a previous agreement that was terminated by Novo after Hims continued to market copycat medications [2]. Group 2: Market Reaction - Following the news of the partnership, Novo's ADRs rose by 2% in after-hours trading, while Hims' shares surged nearly 40% [4]. - The end of the feud is viewed positively for Hims' stock, as noted by Leerink Partners analyst Michael Cherny [3]. Group 3: Strategic Rationale - Novo's decision to partner with Hims again is likely driven by the need to expand market reach and improve performance amid a competitive obesity treatment landscape [6][9]. - The new CEO of Novo is under pressure from investors to reverse a multi-year stock decline, which may have influenced the decision to collaborate with Hims [9]. Group 4: Analyst Insights - Analysts have noted that the rationale for the partnership's announcement may be explained by executives from either company, potentially addressing the poor year-to-date performance of both firms [7]. - Goldman analyst James Quigley recently downgraded Novo's stock from "Buy" to "Hold," indicating a cautious outlook despite the new partnership [10].

Core Viewpoint - Bristol Myers Squibb received U.S. approval for its oral drug Sotyktu to treat adults with active psoriatic arthritis, providing a new treatment option for patients suffering from this autoimmune disease [1][7]. Drug Mechanism - Sotyktu works by selectively targeting tyrosine kinase 2, which is involved in immune-driven inflammation [2]. Clinical Trial Results - In two global Phase 3 studies (POETYK PsA-1 and POETYK PsA-2), patients received either a daily 6-milligram tablet of Sotyktu or a placebo. By Week 16, approximately 54% of patients taking Sotyktu achieved an ACR20 response, compared to 34% and 39% of placebo patients [3][4]. - The treatment group demonstrated a statistically significant benefit, with about 25% of treated patients achieving an ACR50 response and meaningful improvements in minimal disease activity scores, indicating broader relief across joints, skin, and pain [4]. Expert Commentary - Company representatives highlighted the approval as a significant milestone, emphasizing Sotyktu's role in managing both skin and joint symptoms of psoriatic disease. Experts noted improved quality-of-life scores for patients on the treatment during trials [5]. Safety Profile - The safety profile of Sotyktu was similar to previous studies, with common side effects including respiratory infections, mouth ulcers, acne, and elevated muscle enzyme levels. Warnings include risks of infections, viral reactivation, and potential malignancies, necessitating tuberculosis screening before treatment [6]. Market Context - The FDA initially approved Sotyktu in 2022 for moderate-to-severe plaque psoriasis, and the recent approval expands its use to adults with psoriatic arthritis, a condition affecting up to 30% of individuals with psoriasis [7]. Stock Performance - Following the announcement, Bristol-Myers shares fell by 0.28% to $60.12 in after-hours trading [8].